Market research
CRDF Cardiff Oncology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 79M
- P/E ratio
- Not available
- Analyst target
- 5.1
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US14147L1089
- Market cap
- 79M
- P/E ratio
- Not available
- Analyst target
- 5.1
- Dividend yield
- Not available
- Beta
- 1.44
About
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CRDF discussion.
5 years, 4 months ago
Cardiff Oncology, Inc is currently in a long term downtrend where the price is trading 48.4% below its 200 day moving average.
From a valuation standpoint, the stock is 59.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 549.8.
Cardiff Oncology, Inc's total revenue rose by 28.8% to $119K since the same quarter in the previous year.
Its net income has dropped by 55.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Cardiff Oncology, Inc gets an overall score of 2/5.